Teva Pharmaceutical Industries Ltd $ 12.27 0.08 (0.66%)
Warning! GuruFocus has detected 5 Severe warning signs with TEVA. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Teva Pharmaceutical Industries Ltd () from 1990 to Aug 04 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Teva Pharmaceutical Industries stock (TEVA) PE ratio as of Aug 04 2020 is 0. More Details
Teva Pharmaceutical Industries PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Teva Pharmaceutical Industries PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare XTAE:KMDA XTAE:PNAX XTAE:REKA XTAE:PMCN XTAE:MCTC NYSE:ZTS TSE:4502 XTER:MRK HKSE:03692 TSE:4523 SZSE:000661 TSE:4507 SZSE:000538 NSE:SUNPHARMA SZSE:300601 NYSE:CTLT SHSE:600196 OTCPK:MTZPY XSWX:VIFN NAS:PPD
Traded in other countries TEVA.Austria TEV.Germany TEVA.Israel TEVA.Mexico TEVA.Switzerland TEVA.USA
Address 5 Basel Street, Petach Tikva, ISR, 4951033
Headquartered in Israel, Teva Pharmaceutical is the largest generic drug manufacturer in the world with more than 60 manufacturing and R&D facilities. The company was formed in 1901 and has a portfolio of more than 3,500 medicines--roughly one out of nine generic prescriptions in the U.S. is filled with a Teva product. The company also develops branded pharmaceuticals in the central nervous system, oncology, and respiratory categories. Teva's generic drug sales represent about half of total revenue, with branded drug and distribution revenue making up the balance. Teva is an aggressive filer to bring generic drugs to market when brand patents expire and has the most generic products pending FDA approval.